Working together to fight the COVID-19 epidemic - On April 12, 2022
HANGZHOU ALLTEST BIOTECH CO.,LTD. ( hereinafter referred to as "AllTest Bio.") and Zhejiang ZHENDE MEDICAL CO.,LTD. (hereinafter referred to as "Zhende Medical"), a wholly-owned subsidiary of Zhende Medical Products Company Limited, have signed a strategic cooperation agreement in Shaoxing. The two parties will cooperate on the development of the COVID-19 Antigen Test Kit to help prevent and control the epidemic.
Previously, the State Council's Joint Prevention and Control Mechanism for Novel Coronavirus Pneumonia Epidemic issued the "Application Scheme for the Detection of COVID-19 Antigen (Trial)". The two parties have thus launched a close cooperation, with AllTest Bio. providing high-quality and high-yielding COVID-19 Antigen Test kits by virtue of its strong technological R&D and innovation capabilities, while Zhende Medical will play its own advantages and adopt a dual-brand cooperation model to carry out sales and related business on offline and online platforms nationwide. By joining forces, they will be able to protect the health of the general public and contribute to the fight against COVID-19 epidemics.
Gao Fei, Chairman of AllTest Bio. said, "This is a cooperation full of opportunities and win-win for both sides. AllTest Bio. has always been committed to the research and development, production and sales of in vitro diagnostic (IVD) reagents, and has strong production and organizational capabilities in the new crown antigen kit products, and then combined with the national business layout, logistics and distribution channels, professional services and other capabilities of Zhende Medical, giving full play to their respective strengths, join hands to carry a greater social responsibility and play a force for the national fight against the COVID-19 epidemic."
Lu Jianguo, Chairman of Zhende Medical, said at the signing ceremony, "Zhende Medical has been actively fulfilling its responsibilities in the fight against the COVID-19 epidemic, and antigen testing is a new initiative for China to overcome the COVID-19 epidemic, which has the advantages of low cost and reducing the pressure on social screening and testing resources. The cooperation with Aotearoa will enable us to leverage our respective strengths and leverage AllTest’s strong R&D and innovation capabilities and Zhende's nationwide business layout to quickly deliver high-quality products to the front-line of the nation's fight against the epidemic, contributing to the realization of the country's dynamic zero strategy."